Johnson & Johnson News
Strong performance by JNJ puts healthcare ETFs in focus for the coming days.
There's a lot wrong with this market but the companies are part of the solution, not the problem, Cramer asserts.
We're getting some solid reports, but a lot of people don't want to believe it.
Benchmarks finished in the green on Tuesday after blue-chip companies Coca-Cola and Johnson & Johnson reported upbeat quarterly results
Holding back the Dow today is Johnson & Johnson (NYSE:JNJ), which is lagging the broader Dow index with a 51-cent decline (-0.5%) bringing the stock to $98.69.
Leerink increased its price target on Johnson & Johnson (JNJ) to $110, increased its estimates and set an "outperform" rating. The firm cited solid pharma momentum as the reason for the increase.